Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance–Associated Mutations or M184I/V in Proviral DNA

The Journal of Infectious Diseases 2026 Open access

Read full text
Authors: Tracy L. Diamond, Anjana Grandhi, Monica Fuszard, Yayun Xu, Uchechukwu Nwoke, Ying Zhang, Stephanie Olsen Klopfer, Karen A. Eves, Jaime Benner, M. K. Li, Wayne L. Greaves, Rima Lahoulou
+3 more Jason Kim, Michelle C. Fox, Ernest Asante‐Appiah
DOI: 10.1093/infdis/jiag257
Cited by: 1
References: 29

Abstract

BACKGROUND: Doravirine/islatravir (DOR/ISL) is a 2-drug, single-tablet regimen in clinical development for once-daily treatment of adults living with HIV-1. We examined the impact of baseline resistance-associated mutations (RAMs) in proviral DNA on the response to DOR/ISL (100/0.25 mg) in virologically suppressed participants in three phase 3 studies. METHODS: Samples were collected pre-dose from participants in studies P051 (NCT05631093), P052 (NCT05630755), and P054 (NCT05766501) to evaluate RAMs in proviral DNA at baseline. The prevalence of baseline non-nucleoside reverse transcriptase inhibitor (NNRTI) RAMs and M184I/V, and their impact on virologic suppression (HIV-1 RNA

Fields of Study & Subjects

HIV/AIDS drug development and treatment Virus-based gene therapy research HIV Research and Treatment

Publication details

Journal / source
The Journal of Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
234
Issue
3
Pages
e466-e476
Publication date
26 May 2026
Language
EN